All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @socalurologyinstitute on TikTok · 15s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @socalurologyinstitute's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00I'm going to the bridge, I don't care, I love it, I don't care
  2. 0:11I've got this feeling on a summer day when you were gone

Dr. Bellman's estradiol claims on TRT, fact-checked

Dr Gary Bellman | SoCalUrology

TikTok creator

53.4K viewsWatch on TikTok

Quick answer

The video's core claim, embedded in its caption rather than any spoken medical content, is that an estradiol level of 70 pg/mL on TRT is clinically insignificant and does not warrant intervention. This position has partial support in recent literature challenging aggressive aromatase inhibitor use in TRT patients, but a blanket dismissal ignores assay validity, individual symptom burden, and known risks of both estradiol excess and suppression. No spoken clinical guidance was actually provided in the transcript.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

TRT social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 9 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For Dr. Bellman's estradiol claims on TRT, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

Dr. Bellman's estradiol claims on TRT, fact-checked is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Claim path

Keep researching this testosterone and trt video claims cluster

Best for searchers turning TRT social claims into a safer lab-backed provider discussion.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "Dr. Bellman's estradiol claims on TRT, fact-checked" from Dr Gary Bellman | SoCalUrology. We read the clip as a TRT social video fact-checks claim about Testosterone, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The video's core claim, embedded in its caption rather than any spoken medical content, is that an estradiol level of 70 pg/mL on TRT is clinically insignificant and does not warrant intervention.

The reason this review is not generic is the source wording and the canonical claim label "trt my estradiol is 70 on trt i don t care trt estradiol ar." In this clip, the useful excerpt is: "I'm going to the bridge, I don't care, I love it, I don't care I've got this feeling on a summer day when you were gone" That wording changes the review because it points to Testosterone evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Cardiovascular Safety of Testosterone-Replacement Therapy (2023), Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline (2010), and Functional testosterone deficiency in aging men: Clinical impact, diagnostic pathways, and treatment strategies (2026), plus the creator's own wording. Testosterone decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Finkelstein et al.
People who land here are usually comparing the Testosterone claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Testosterone guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

The video's core claim, embedded in its caption rather than any spoken medical content, is that an estradiol level of 70 pg/mL on TRT is clinically insignificant and does not warrant intervention.

FormBlends verdict

Testosterone evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • The video's core claim, embedded in its caption rather than any spoken medical content, is that an estradiol level of 70 pg/mL on TRT is clinically insignificant and does not warrant intervention. This position has partial support in recent literature challenging aggressive aromatase inhibitor use in TRT patients, but a blanket dismissal ignores assay validity, individual symptom burden, and known risks of both estradiol excess and suppression. No spoken clinical guidance was actually provided in the transcript.
  • Standard immunoassay estradiol tests are not validated for men and can read falsely elevated; LC-MS/MS is the recommended assay for accurate male estradiol measurement.
  • Finkelstein et al. (2013, NEJM) found both testosterone and estradiol independently contribute to libido, sexual function, and lean body mass in men, meaning estrogen suppression is not without consequence.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • Standard immunoassay estradiol tests are not validated for men and can read falsely elevated; LC-MS/MS is the recommended assay for accurate male estradiol measurement.
  • Finkelstein et al. (2013, NEJM) found both testosterone and estradiol independently contribute to libido, sexual function, and lean body mass in men, meaning estrogen suppression is not without consequence.
  • Ramasamy et al. (2014, BJU International) found anastrozole raised testosterone levels in hypogonadal men but raised concerns about lipid and bone metabolism with prolonged use.
  • Travison et al. (2017, JCEM) showed that estradiol deficiency in men negatively affects bone mineral density, which argues against routine aggressive aromatase inhibitor use.
  • An estradiol of 70 pg/mL on TRT may be asymptomatic and acceptable in one patient and associated with gynecomastia or other symptoms in another; no single number applies universally.
  • The TRT community's historical over-reliance on aromatase inhibitors to chase low estradiol targets is not well supported by current clinical evidence, but replacing that with blanket dismissal is not an improvement.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @socalurologyinstitute actually say?

Honestly? Almost nothing medically substantive. The transcript is a fragment of a pop song, specifically what appears to be lyrics from "I Gotta Feeling" by the Black Eyed Peas, paired with a caption claiming "My estradiol is 70 on TRT; I don't care." The clinical content lives in the caption, not the words spoken. So the actual medical claim being broadcast to 53,000+ viewers is: an estradiol level of 70 pg/mL during testosterone replacement therapy is not worth worrying about, and by extension, neither is estrogen management generally.

That framing, delivered with a song and a shrug, carries real weight when it comes from an account branding itself as a urology institute. The hashtags for arimidex and anastrozole suggest the implicit subtext is that aromatase inhibitors are unnecessary. That's the claim worth examining.

Does the science back this up?

Partially, and only in specific contexts. The evidence that moderate estradiol elevation during TRT causes harm is genuinely weaker than many TRT clinics have historically implied. But "I don't care" at 70 pg/mL glosses over real nuance.

The often-cited "normal" male estradiol range runs roughly 10-40 pg/mL on standard assays, though the more accurate liquid chromatography-mass spectrometry (LC-MS/MS) assay shifts those goalposts. Travison et al. (2017, Journal of Clinical Endocrinology and Metabolism) found that estradiol plays a key role in male libido and bone density, and that suppressing it aggressively with aromatase inhibitors actually worsens outcomes. Finkelstein et al. (2013, NEJM) demonstrated that both testosterone and estradiol contribute independently to sexual function and body composition in men. So the "estrogen is always the enemy" narrative that has driven aggressive AI prescribing in TRT clinics is not well supported.

However, estradiol at 70 pg/mL is not nothing. Some men are symptomatic at that level, some are not. Individual variation is large, assay type matters enormously, and blanket dismissal is not the same as evidence-based reassurance.

What did they get wrong (or right)?

They get partial credit for pushing back against reflexive estrogen suppression. The TRT community has over-relied on aromatase inhibitors for years, often based on symptom checklists with poor specificity and the unsupported assumption that any estradiol above 30 pg/mL needs correction. Ramasamy et al. (2014, BJU International) showed that anastrozole use in hypogonadal men produced testosterone increases but raised concerns about lipid profiles and bone metabolism with long-term use.

Where this video fails is in the delivery. A blanket "I don't care" communicated to tens of thousands of people managing their own TRT, many without close clinical supervision, is irresponsible framing. Estradiol at 70 pg/mL can be associated with gynecomastia progression in predisposed individuals, and context like breast tissue sensitivity, cardiovascular history, and assay methodology genuinely matters. Dismissing it without those caveats teaches the wrong lesson, even if the lesson adjacent to it has some merit.

What should you actually know?

If you are on TRT and your estradiol comes back elevated, the first question is what assay was used. Standard immunoassay estradiol tests are not validated for men and frequently read falsely high. The LC-MS/MS assay is the appropriate test for men. Many "high" estradiol results in TRT patients are assay artifacts.

Second, symptoms matter more than a number in isolation. Gynecomastia, water retention, or mood changes paired with an elevated estradiol is a different clinical picture than an elevated number with no symptoms.

Third, aromatase inhibitors like anastrozole carry real risks. They are not benign estrogen-management tools. Long-term use can negatively affect bone mineral density, lipid profiles, and cognitive function. Aggressive use to chase an arbitrary estradiol target is not supported by current evidence.

Finally, individual thresholds vary. A level of 70 pg/mL might be genuinely fine for one patient and clinically relevant for another. Anyone managing TRT without a physician who actually reviews labs in context is taking on real risk, regardless of what a urology-branded TikTok account posts.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Dr Gary Bellman | SoCalUrology · TikTok creator

53.4K views on this video

My estradiol is 70 on trt; I don’t care! #trt #estradiol #arimidex #anastrazole #testosteronetherapy

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about standard immunoassay estradiol tests?

Standard immunoassay estradiol tests are not validated for men and can read falsely elevated; LC-MS/MS is the recommended assay for accurate male estradiol measurement.

What does the video say about finkelstein et al. (2013, nejm) found both testosterone?

Finkelstein et al. (2013, NEJM) found both testosterone and estradiol independently contribute to libido, sexual function, and lean body mass in men, meaning estrogen suppression is not without consequence.

What does the video say about ramasamy et al. (2014, bju international) found anastrozole raised testosterone?

Ramasamy et al. (2014, BJU International) found anastrozole raised testosterone levels in hypogonadal men but raised concerns about lipid and bone metabolism with prolonged use.

What does the video say about travison et al. (2017, jcem) showed?

Travison et al. (2017, JCEM) showed that estradiol deficiency in men negatively affects bone mineral density, which argues against routine aggressive aromatase inhibitor use.

What does the video say about an estradiol of 70 pg/ml on trt may be asymptomatic?

An estradiol of 70 pg/mL on TRT may be asymptomatic and acceptable in one patient and associated with gynecomastia or other symptoms in another; no single number applies universally.

What does the video say about the trt community's historical over-reliance on aromatase inhibitors to chase?

The TRT community's historical over-reliance on aromatase inhibitors to chase low estradiol targets is not well supported by current clinical evidence, but replacing that with blanket dismissal is not an improvement.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Dr Gary Bellman | SoCalUrology, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.